These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 7540551

  • 1. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
    Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, Ciardi L, Sacchetti GM, Inglese E.
    Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
    Wang TY, Chen XP, Li XS, Jia Yx, Cheng J, Zhang JH, Cai L, Zhang Z, Gong K, He ZS, Zhou LQ.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug 18; 44(4):528-34. PubMed ID: 22898839
    [Abstract] [Full Text] [Related]

  • 5. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
    Kageyama Y, Kihara K, Kamata S, Nagahama K, Yonese J, Fukuda H, Tosaka A, Nagamatsu H, Ishizaka K, Tsujii T, Kitahara S, Morita T, Oshima H.
    Hinyokika Kiyo; 1996 Mar 18; 42(3):197-9. PubMed ID: 8619388
    [Abstract] [Full Text] [Related]

  • 6. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV, Bennett A, Narahari K, Hughes O, Rees J, Kynaston H.
    BJU Int; 2017 Nov 18; 120(5B):E59-E63. PubMed ID: 28317247
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Metastasis on bone scan with low prostate specific antigen (≤20 ng/ml) and Gleason's score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines?
    Zaman MU, Fatima N, Sajjad Z.
    Asian Pac J Cancer Prev; 2011 Nov 18; 12(6):1529-32. PubMed ID: 22126493
    [Abstract] [Full Text] [Related]

  • 9. The value of a baseline bone scan in patients with newly diagnosed prostate cancer.
    Lin K, Szabo Z, Chin BB, Civelek AC.
    Clin Nucl Med; 1999 Aug 18; 24(8):579-82. PubMed ID: 10439178
    [Abstract] [Full Text] [Related]

  • 10. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
    Wolff JM, Bares R, Jung PK, Buell U, Jakse G.
    Urol Int; 1996 Aug 18; 56(3):169-73. PubMed ID: 8860738
    [Abstract] [Full Text] [Related]

  • 11. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
    Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G.
    Eur Urol; 1998 Aug 18; 33(4):376-81. PubMed ID: 9612680
    [Abstract] [Full Text] [Related]

  • 12. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M, Muscat J.
    Abdom Imaging; 1996 Aug 18; 21(4):364-7. PubMed ID: 8661585
    [Abstract] [Full Text] [Related]

  • 13. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
    Bruwer G, Heyns CF, Allen FJ.
    Eur Urol; 1999 Aug 18; 35(3):223-7. PubMed ID: 10072624
    [Abstract] [Full Text] [Related]

  • 14. MRI of the skeleton in prostate cancer staging.
    Rydh A, Lundblad M, Ahlström KR, Tavelin B, Stattin P.
    Scand J Urol Nephrol; 2003 Aug 18; 37(3):222-5. PubMed ID: 12775281
    [Abstract] [Full Text] [Related]

  • 15. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.
    Al-Ghazo MA, Ghalayini IF, Al-Azab RS, Bani-Hani I, Barham A, Haddad Y.
    Int Braz J Urol; 2010 Aug 18; 36(6):685-91; discussion 691-2. PubMed ID: 21176275
    [Abstract] [Full Text] [Related]

  • 16. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M, Gion M, Bonazza A, Delli Ponti US, Bolgan A, Contemori GP, Barioli P, Capitanio G, Pecori B, Omacini S.
    Eur Urol; 1995 Aug 18; 27(4):295-300. PubMed ID: 7544735
    [Abstract] [Full Text] [Related]

  • 17. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
    Haukaas S, Roervik J, Halvorsen OJ, Foelling M.
    Br J Urol; 1997 May 18; 79(5):770-6. PubMed ID: 9158517
    [Abstract] [Full Text] [Related]

  • 18. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients.
    Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, Bagiella E, Singh A, Ennis RD.
    Int J Radiat Oncol Biol Phys; 2000 Dec 01; 48(5):1443-6. PubMed ID: 11121646
    [Abstract] [Full Text] [Related]

  • 19. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
    Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC.
    JAMA; 1993 Jan 06; 269(1):57-60. PubMed ID: 7677962
    [Abstract] [Full Text] [Related]

  • 20. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer.
    Rydh A, Tomic R, Tavelin B, Hietala SO, Damber JE.
    Scand J Urol Nephrol; 1999 Apr 06; 33(2):89-93. PubMed ID: 10360447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.